Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued to investors on Sunday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

NASDAQ EGRX opened at $1.19 on Friday. Eagle Pharmaceuticals has a one year low of $0.00 and a one year high of $6.81. The company’s 50 day moving average price is $0.68 and its 200 day moving average price is $1.99.

Institutional Trading of Eagle Pharmaceuticals

Several large investors have recently added to or reduced their stakes in EGRX. Jane Street Group LLC purchased a new stake in shares of Eagle Pharmaceuticals in the third quarter worth about $96,000. Creative Planning purchased a new position in Eagle Pharmaceuticals in the 3rd quarter worth approximately $59,000. Cubist Systematic Strategies LLC purchased a new position in Eagle Pharmaceuticals in the 2nd quarter worth approximately $145,000. DGS Capital Management LLC grew its position in Eagle Pharmaceuticals by 44.9% in the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after acquiring an additional 22,239 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Eagle Pharmaceuticals during the third quarter valued at approximately $453,000. 85.36% of the stock is currently owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.